GLPwatch
Bydureon for Chronic kidney disease
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCBydureon (exenatide) is not FDA-approved for chronic kidney disease, and any use for this condition is off-label or investigational. Research includes studies on its renal effects, cardiovascular and renal outcomes in patients with type 2 diabetes, and animal models, but these do not establish efficacy for treating chronic kidney disease.
AI summary of the sources below.
| Drug | Bydureon (exenatide) |
|---|---|
| Condition | Chronic kidney disease |
| Approval status | Investigational / off-label |
| Research papers | 36 |
Bydureon is not FDA-approved for chronic kidney disease; the research below reflects investigational or off-label study only.
Research on exenatide for chronic kidney disease (36)
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
- Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
- Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.
- Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
- The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
- Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
- Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
- Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide.
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.
- Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats.
- Acute tubulointerstitial nephritis following treatment with exenatide.
- Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
- Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells.
- Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy.
- Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.
- Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.
- Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
- Exenatide and renal failure.
- An experimental study of exenatide effects on renal injury in diabetic rats1.
- Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
- Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
- SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease.
- Comparison of nephron-protective effects of enalapril and GLP analogues (exenatide) in diabetic nephropathy.